Sulphasalazine is widely used as a second line agent for the treatment of rheumatoid arthritis (RA). Current dose regimens usually commence at 500 mg/day, and thereafter use a progressive increase in dose by 500 mg/day increments to a target dose of 40 mg/kg.' However, toxicity (particularly mucocutaneous and gastrointestinal adverse effects) remains a relatively common reason for discontinuation of treatment in the first year, in contrast to failed efficacy, which is the predominant cause of discontinuation of treatment at a later stage.24 The beneficial effect of desensitisation with low dose sulphasalazine over three weeks was reported in an open uncontrolled trial that examined the effect of reintroduction of sulphasalazine in patients who had previously experienced mucocutaneous toxicity with this drug. 7 overall incidence of adverse effects, whether transient or leading to discontinuation of drug, was similar in each group: 65-8% in patients desensitised actively and 61d1% in those receiving placebo.
Discussion Toxicity remains the major limiting factor in the use of disease modifring anti-rheumatic drugs (DMARDs) in treatment of rheumatoid arthritis. This issue is particularly pertinent because the use of DMARDs is advocated at an early stage in disease progression, at a time when the prognosis is unclear and, accordingly, the risk/benefit ratio of treatment is less distinct than that for treatment of patients with advanced, well characterised disease. Previous studies indicate that sulphasalazine is comparable to other DMARDs in both its toxicity profile and its efficacy.2 4 9 10 Increasingly, it is offered to patients with inflammatory disease without the supervision of specialist clinics. In this study we have investigated the possible role of drug desensitisation for reduction of the early adverse effects that often lead to discontinuation of sulphasalazine treatment, thereby allowing greater therapeutic benefit to be obtained from its use in the treatment of RA.
In order to demonstrate a reduction in adverse events, even when these occur relatively commonly, large numbers of patients are required. Although power calculations indicated a priori that our study possessed the requisite sample size to detect a 50% reduction in adverse effects up to six months, it is unlikely that the trial could have detected a smaller (for example 25%) reduction in risk, or a reduction in individual side effects such as rash. However, even though the present study did not have the statistical power to exclude an effect of low dose desensitisation for subgroups of toxicity, no trend towards a difference in mucocutaneous events (rash, mouth ulcers) was observed. As the positive effects of desensitisation are likely to be evident soon after commencement of drug treatment, it seems unlikely that an effect would be manifest in a longer study. 
